Skip to main navigation Skip to search Skip to main content

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)

Project: Research

Project Details

StatusActive
Effective start/end date03/2/26 → 09/1/30

Funding

  • Fortrea Incorporated: $30,444.00